Department of Endocrinology and Metabolism, The First Affiliated Hospital of Datong University, Datong, Shanxi, China.
Shanghai Benemae Pharmaceutical Corporation, Shanghai, China.
Arch Endocrinol Metab. 2021 Nov 3;65(4):421-427. doi: 10.20945/2359-3997000000388. Epub 2021 Jul 16.
To evaluate the effect of beinaglutide on weight loss and plasma protein patterns of inflammation/obesity relevant cytokines and biomarkers.
This study involved 36 adult patients with a body mass index (BMI) of ≥ 24 kg/m and T2DM. Beinaglutide was administered for three months. Changes in body weight, fasting plasma glucose (FPG) level, 2 h postprandial plasma glucose (2h-PG) level, glycosylated hemoglobin (HbA1c) level, BMI and visceral and subcutaneous fat areas were measured at baseline and after three months of treatment. In addition, relevant inflammation/obesity cytokines and biomarkers were measured.
After three months, beinaglutide treatment led to significant changes, including in body weight, BMI, FPG level, HbA1c level, visceral and subcutaneous fat areas. In addition, serpin E1, leptin, C-reaction protein (CRP) and tumor necrosis factor-α (TNF-α) also decreased significantly. The plasma protein concentrations of CRP (Log2 transformed) were found to be positively correlated with the percentage of weight loss (R = 0.514 and p-value = 0.021).
Beinaglutide treatment resulted in weight loss, plasma glucose control and anti-inflammatory effects in patients with T2DM and overweight/obesity.
评估贝那鲁肽对体重减轻和与炎症/肥胖相关的细胞因子和生物标志物的血浆蛋白谱的影响。
本研究纳入了 36 名 BMI≥24kg/m²且患有 T2DM 的成年患者。给予贝那鲁肽治疗三个月。在基线和治疗三个月时，测量体重、空腹血糖（FPG）水平、餐后 2 小时血糖（2h-PG）水平、糖化血红蛋白（HbA1c）水平、BMI 以及内脏和皮下脂肪面积的变化。此外，还测量了相关炎症/肥胖细胞因子和生物标志物。
治疗三个月后，贝那鲁肽治疗导致体重、BMI、FPG 水平、HbA1c 水平、内脏和皮下脂肪面积显著变化。此外，丝氨酸蛋白酶抑制剂 E1、瘦素、C 反应蛋白（CRP）和肿瘤坏死因子-α（TNF-α）也显著降低。CRP（Log2 转换）的血浆蛋白浓度与体重减轻百分比呈正相关（R=0.514，p 值=0.021）。
贝那鲁肽治疗可导致 T2DM 和超重/肥胖患者体重减轻、血糖控制和抗炎作用。
Zotero 插件